entertainment -WSS

entertainment

author：leisure time 2025-10-01 05:23:51 - browse：54

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — The booming obesity market is attracting another player, as pharma giant Roche said Monday it was acquiring Carmot Therapeutics and the company’s line of weight loss drug candidates for $2.7 billion upfront.

The deal for Carmot, which is based in Berkeley, Calif., includes additional milestone payments of up to $400 million. Carmot is privately held, though it had filed paperwork last month for an initial public offering.

As part of the deal, Roche is gaining three experimental obesity medicines from Carmot, which are in Phase 1 or Phase 2 testing, as well as preclinical programs. While two are injectable treatments, one is being developed as an oral drug. They all target GLP-1 hormone receptors, while two are also designed to work via receptors for another hormone called GIP.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Why depression after traumatic brain injury is distinct

leisure time

WSS

As AI in medicine takes off, can 'human in the loop' prevent harm?

‘Oppenheimer’ and the risks of AI in health care

NIH launches clinical trials and new research office for long Covid

EQRx, failed developer of low

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Amid AI frenzy, a top HHS official's quest to create safeguards

hotspot

entertainment

leisure time

Heart attack and stroke risk calculators need revising

How many hemophilia patients actually want gene therapy?

Medical leaders decry Supreme Court decision on affirmative action

Adults seen as increasingly susceptible to measles

Psychedelics group wrestles with new pharma identity

Physician groups backed by private equity giant lobby on mergers

23andMe had bad news about my health. I wish a person had delivered it

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Affirmative action in medical school literally saved lives

‘Oppenheimer’ and the risks of AI in health care

focus

National panel will explore requiring free Covid tests

EQRx, failed developer of low

What to expect as Trump is arraigned on his Jan 6. indictment

Why scientists need input from humanists on sensitive research

What to expect as Trump is arraigned on his Jan 6. indictment

Micronoma's microbiome cancer diagnostic approach under fire

leisure time

Wikipedia

explore

knowledge